Amphastar Pharmaceuticals to Present at the Raymond James Life Sciences and MedTech Healthcare Conference
June 14, 2019 06:00 ET
|
Amphastar Pharmaceuticals, Inc.
RANCHO CUCAMONGA, Calif., June 14, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, will be presenting at the Raymond James Life...
Amphastar Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference
May 31, 2019 06:00 ET
|
Amphastar Pharmaceuticals, Inc.
RANCHO CUCAMONGA, Calif., May 31, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President and Bill Peters, CFO, will be presenting at...
Amphastar Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference 2019
May 10, 2019 06:00 ET
|
Amphastar Pharmaceuticals, Inc.
RANCHO CUCAMONGA, Calif., May 10, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President and Bill Peters, CFO, will be presenting at...
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2019
May 09, 2019 16:05 ET
|
Amphastar Pharmaceuticals, Inc.
RANCHO CUCAMONGA, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31,...
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2019
May 06, 2019 06:00 ET
|
Amphastar Pharmaceuticals, Inc.
RANCHO CUCAMONGA, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its first quarter of 2019 ended March...
Amphastar Pharmaceuticals Receives FDA Approval for Enoxaparin Sodium Injection 300mg/3mL (100mg/mL) Multiple Dose Vial
March 19, 2019 06:00 ET
|
Amphastar Pharmaceuticals, Inc.
RANCHO CUCAMONGA, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (FDA) granted approval of its...
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2018
March 12, 2019 16:05 ET
|
Amphastar Pharmaceuticals, Inc.
Reports Net Revenues of $89.7 Million for the Three Months Ended December 31, 2018 RANCHO CUCAMONGA, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)...
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 12, 2019
March 07, 2019 16:01 ET
|
Amphastar Pharmaceuticals, Inc.
RANCHO CUCAMONGA, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its fourth quarter of 2018 ended...
Amphastar Pharmaceuticals, Inc. Announces Launch of Primatene® MIST to Nationwide Retail Pharmacies
January 03, 2019 06:00 ET
|
Amphastar Pharmaceuticals, Inc.
RANCHO CUCAMONGA, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced today that Primatene® MIST has been launched. Primatene® MIST is an epinephrine...
Amphastar Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference 2018
November 20, 2018 16:05 ET
|
Amphastar Pharmaceuticals, Inc.
RANCHO CUCAMONGA, Calif., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO will be presenting at the 30th Annual Piper Jaffray...